Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment.

Masato ShikataKenji AshidaYuka GotoAyako NagayamaShimpei IwataMamiko YanoNao HasuzawaKento HaraKazutoshi MawatariKiyohiko SakataMunehisa TsurutaNobuhiko WadaMasatoshi Nomura

Published in: Clinical case reports (2020)

Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type-5 stimulation. GLP-1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.

Keyphrases

diabetic rats
rheumatoid arthritis
case report
high glucose
risk assessment
drug induced
endothelial cells